Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2010 Financial Results
Date:2/24/2011

ns for more information on ViroPharma and our business.

Disclosure NoticeCertain statements in this press release contain forward-looking statements that involve a number of risks and uncertainties. Forward-looking statements provide our current expectations or forecasts of future events. Forward looking statements in this press release include our financial guidance for 2011, our ability to continue to successfully commercialize Cinryze, our ability to complete manufacturing scale up procedures, and receive regulatory approvals in the time frames anticipated, our ability to manufacture specified quantities of Cinryze utilizing the existing manufacturing process or additional manufacturing procedures; our ability to develop life cycle management plans for Cinryze, including designing and commencing clinical studies for additional indications, and pursuing regulatory approvals in additional territories; and our ability to conduct additional studies in the timeframes we anticipate and generate positive results with a Cinryze subcutaneous formulation, Cinryze for antibody mediated rejection and delayed graft function, as well as VP20621 for recurrence of C. difficile.

Our actual results may vary depending on a variety of factors, including:

  • the development of competitive generic versions of oral Vancocin;
  • our ability to receive regulatory approval for the use of Cinryze for additional indications and formulations and in additional territories including the EU in the timeframes we anticipate or at all;
  • manufacturing, supply or distribution interruptions, including but not limited to our ability to acquire adequate supplies of Vancocin and Cinryze to meet demand for each product;
  • our ability to increase manufacturing capacity for Cinryze and the timing and results thereof;
  • our ability to receive necessary regulatory approvals related to manufacturing capacity increases for Cinryze;
  • the
    '/>"/>

  • SOURCE ViroPharma Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related biology technology :

    1. ViroPharma to Present at Three September Healthcare Conferences
    2. ViroPharma to Present at Three October Healthcare Conferences
    3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
    4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
    5. ViroPharma to Present at Three November Healthcare Conferences
    6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
    7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
    8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
    9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
    10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
    11. ViroPharma to Present at Two June Healthcare Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/27/2014)... Guggenheim Securities, the investment banking and capital ... of veteran equity analyst Charles "Tony" Butler as a ... focus on the biotech/biopharma sector. " Tony ... and a broad network of relationships in his industry," ... Head of Equities at Guggenheim Securities. "His insights will ...
    (Date:8/27/2014)... Research and Markets has announced ... & Paper Industry Report 2014" report to their ... & Paper Industry Report 2014 is a professional and ... enzyme for pulp & paper industry. The ... definitions, classifications, applications and industry chain structure. The enzyme ...
    (Date:8/27/2014)... 27, 2014 Tris Pharma, a specialty pharmaceutical ... announced that it has been selected as an award ... 2014 Awards for Excellence competition in the ... panel of judges from SCORE (Counselors to America,s Small ... be honored at a gala event to be held ...
    (Date:8/27/2014)... After the boom of the energy drink ... craze is going to be the stress relief drinks. ... Stress Relief energy pattern which can be applied to ... beverage, including minerals, herbs and liquids. Stress Relief generates ... into rapid recovery and helping to adapt more quickly. ...
    Breaking Biology Technology:Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Global Enzyme for Pulp & Paper Industry Report 2014 2Tris Pharma Selected as an award winner in the New Jersey Business & Industry Association's 2014 Awards for Excellence 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4
    ... Calif., June 5 /PRNewswire-FirstCall/ - BioMarin Pharmaceutical,Inc. (Nasdaq ... its third,enzyme replacement therapy (ERT) for the treatment ... BioMarin plans to initiate a Phase,1/2 clinical trial ... two MPS drugs on the market, we plan ...
    ... ) notes that FDA has published a notice of a ... to,be held on July 23, 2008. The Committee will address ... " ... presentations from the Office of Generic Drugs (OGD) ... treat gastrointestinal (GI) conditions ... " For over ...
    ... Will be Presented at the American Society for Mass ... 56th ASMS Conference in Denver, June ... Inc.,(Nasdaq: BNVI ) today announced that it has ... platform that allows for the rapid, specific, sensitive,automated quantification ...
    Cached Biology Technology:BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome 2BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome 3BioMarin Announces Program for ERT for Treatment of MPS IVA - Morquio A Syndrome 4Viropharma Comments On Upcoming FDA Advisory Committee Meeting 2Viropharma Comments On Upcoming FDA Advisory Committee Meeting 3Bionovo Develops a High Throughput LC-MS/MS Method for Simultaneous Quantification of Multiple Bioactive Compounds 2Bionovo Develops a High Throughput LC-MS/MS Method for Simultaneous Quantification of Multiple Bioactive Compounds 3
    (Date:8/27/2014)... may not be getting effective doses of the HIV ... The initial dosing studies, completed before the drug was ... a protein that is key to removing maraviroc from ... maximum levels of the protein including nearly half ... their bodies compared to those who lack the protein ...
    (Date:8/27/2014)... found in forests has created a thriving habitat for ... new University of Georgia study has found. , Japanese ... the early 1900s, is one of the most pervasive ... dozen states in the past century, particularly in the ... can survive in widely diverse ecosystems and has been ...
    (Date:8/27/2014)... entering what is described by the Volunteer Wildfire Services ... Eastern Cape provincial government warned residents in certain parts ... and veld fires. A high veld fire danger ... the coast in the Great Kei and Mnquma area. ... during thunderstorms. The thunderstorms bring lightning strikes and ...
    Breaking Biology News(10 mins):Dosage of HIV drug may be ineffective for half of African-Americans 2More wolf spiders feasting on American toads due to invasive grass, UGA study shows 2More wolf spiders feasting on American toads due to invasive grass, UGA study shows 3
    ... reporting dramatic new real-world evidence supporting the idea that ... It appears in a new study showing a connection ... stored drinking water, and health in households in a ... Environmental Science & Technology , a semi-monthly journal. ...
    ... , Menlo Park, Calif. The U.S. Department of ... of the Linac Coherent Light Source (LCLS), the world,s ... laser at the laboratory. The LCLS, which began operation ... laser light which are already providing new insights into ...
    ... project of the European Union has, in addition to the ... of stakeholders interested in making healthier cereal foods as part ... continue the activities and work of the HEALTHGRAIN project which ... Sweden. The HEALTHGRAIN Forum will be the future platform ...
    Cached Biology News:First X-ray laser's early success brings approval for next-phase facility 2The HEALTHGRAIN Forum will work for cereal foods and health 2
    Multidrop Micro high speed 1 l bulk reagent dispenser rapidly, precisely and accurately dispenses microvolumes of 1-50 l into 384- and 96-well microplates....
    ...
    ...
    Buckets for tube holder inserts...
    Biology Products: